Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) has treated the first five patients in its study evaluating eftilagimod alpha (efti) in conjunction with standard of care chemotherapy
- No additional safety signs were observed during the study, which is the first time a triple combination therapy with an anti-PD-1 therapy has been administered
- The study will continue to recruit up to 20 patients suffering various solid tumours, with additional results expected in 2022
- Immutep is up 1.05 per cent on the market this morning, with shares trading at 48 cents at 10:30 am AEDT
Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Efti is Immutep’s lead product candidate, a soluble LAG-3 fusion protein which is being developed for the treatment of cancer and autoimmune disease.
No additional safety signs were observed during the study, which is the first time a triple combination therapy with an anti-PD-1 therapy has been administered.
The trial will see patients receive 30-milligram subcutaneous doses of efti every two weeks in conjunction with the other treatment, with the aim to assess the safety, tolerability, and efficacy of the combination.
Lead investigator of the study, Professor Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF, said the INSIGHT-003 study has commenced well.
“We are very pleased with the safety of the triple combination so far and all patients are still participating in the study,” the lead investigator said.
“This is important as it is the first time patients have received a triple combination therapy with efti.”
The study will continue to recruit up to 20 patients with various solid tumours, with additional results expected in 2022.
Immutep is up 1.05 per cent on the market this morning, with shares trading at 48 cents at 10:30 am AEDT.
